FY2025 EPS Estimate for Cogent Biosciences Raised by Analyst

Cogent Biosciences, Inc. (NASDAQ:COGT) – Equities research analysts at Wedbush lifted their FY2025 earnings estimates for Cogent Biosciences in a report issued on Monday, November 3rd. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings of ($1.99) per share for the year, up from their previous estimate of ($2.21). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences’ Q4 2025 earnings at ($0.44) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.72) EPS.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Tuesday, August 5th. The technology company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02.

Several other research firms also recently weighed in on COGT. Robert W. Baird upped their price objective on shares of Cogent Biosciences from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Tuesday, July 8th. Citigroup raised their price target on shares of Cogent Biosciences from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, July 18th. Guggenheim boosted their price objective on Cogent Biosciences from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, August 25th. Raymond James Financial started coverage on shares of Cogent Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $30.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cogent Biosciences in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.83.

Cogent Biosciences Stock Performance

Shares of NASDAQ:COGT opened at $14.13 on Wednesday. The firm has a market cap of $1.61 billion, a P/E ratio of -7.94 and a beta of 0.41. Cogent Biosciences has a 52-week low of $3.72 and a 52-week high of $17.15. The business’s 50 day simple moving average is $14.25 and its two-hundred day simple moving average is $10.32.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of COGT. Arizona State Retirement System raised its position in shares of Cogent Biosciences by 18.0% during the 1st quarter. Arizona State Retirement System now owns 20,567 shares of the technology company’s stock valued at $123,000 after buying an additional 3,142 shares in the last quarter. CWM LLC raised its position in Cogent Biosciences by 11,869.9% during the first quarter. CWM LLC now owns 8,738 shares of the technology company’s stock valued at $52,000 after purchasing an additional 8,665 shares in the last quarter. Swiss National Bank lifted its stake in Cogent Biosciences by 17.5% during the first quarter. Swiss National Bank now owns 139,100 shares of the technology company’s stock worth $833,000 after purchasing an additional 20,700 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Cogent Biosciences by 77.9% in the 1st quarter. Invesco Ltd. now owns 68,743 shares of the technology company’s stock worth $412,000 after purchasing an additional 30,102 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Cogent Biosciences in the 1st quarter worth about $1,401,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.